Imagine a world where children with allergic asthma could find relief from those pesky house dust mites lurking in their pillows and carpets, thanks to a simple daily tablet under the tongue. That's the exciting promise of sublingual immunotherapy (SLIT), a treatment that gently introduces allergens to the body to build tolerance over time. But here's where it gets controversial: a major study on this approach hit some unexpected roadblocks during the COVID-19 pandemic, leaving us to wonder if the therapy truly works or if outside factors are clouding the picture. Let's dive into the details of this eye-opening research, breaking it down step by step so even beginners can follow along.
For starters, house dust mites—those tiny critters that thrive in warm, humid environments—are a common trigger for allergies and asthma in kids. Sensitization to them early on can significantly raise the risk of developing allergic asthma, a condition where airways become inflamed and narrowed, leading to symptoms like wheezing, coughing, and shortness of breath. In adults, allergen immunotherapy has shown real promise in taming these reactions, but solid evidence for its use in children has been scarce. That's why a team led by Graham Roberts from the David Hide Asthma and Allergy Centre at St Mary's Hospital conducted the MT-11 trial, a rigorous phase 3 study designed to fill that gap.
The trial was a randomized, double-blind, placebo-controlled effort involving 533 children aged 5 to 17 years who had house dust mite-related allergic asthma and a history of recent asthma flare-ups, even while on standard treatments like inhaled corticosteroids or long-acting beta-agonists. These flare-ups, known as clinically relevant asthma exacerbations, are serious episodes that often require extra medication, emergency care, or hospitalization—they're the primary way doctors measure how well asthma treatments are controlling the disease.
Participants were randomly assigned to take either a daily tablet containing a standardized quality (SQ) house dust mite SLIT extract or a placebo for 24 to 30 months. The goal? To see if the SLIT tablet could reduce the yearly rate of those exacerbations compared to placebo. And this is the part most people miss: despite the therapy's potential, the study didn't meet its main objective. Why? The COVID-19 pandemic dramatically slashed asthma exacerbation rates across the board, making it hard to spot clear differences between the treatment and placebo groups.
In fact, the annual rate ratio for clinically relevant exacerbations was 0.89 (with a 95% confidence interval of 0.60 to 1.30), hinting at a possible benefit from the SLIT tablet but not enough to prove it was definitively better than placebo. Intriguingly, the treatment group showed positive changes in specific antibodies—like house dust mite-specific IgE, IgG4, and IgE-blocking factor (IgE-BF)—which weren't seen in the placebo group. These shifts suggest the therapy was working at an immune level, potentially reprogramming the body's response to allergens.
The researchers noted that overall, the annualized exacerbation rates were low in both groups: 0.21 in the SLIT-tablet group and 0.18 in the placebo group. They attributed this largely to a whopping 67% drop in asthma exacerbations during the pandemic compared to pre-pandemic levels. Before COVID-19, the placebo group in the trial had an exacerbation rate of 0.39, which was lower than the anticipated 1.4 based on an older study by Lanier and colleagues. That earlier research involved kids with poorly controlled asthma despite medium- or high-dose inhaled corticosteroids, sometimes combined with other therapies.
But here's a fascinating twist: the actual rates in MT-11 aligned more closely with later pediatric trials, where placebo groups saw yearly exacerbation rates ranging from 0.43 to 0.87. This points to broader improvements in children's asthma management over recent years. Factors like reduced outdoor pollution, better access to healthcare, enhanced self-management education, and—critically—fewer respiratory tract infections due to pandemic-era social distancing and restrictions all played a role. For beginners, think of it like this: viruses, much like dust mites, can spark asthma attacks, and with fewer colds and flu circulating, kids had fewer triggers.
Other explanations include children being more vigilant about seeking hospital care for asthma symptoms or wheezing, and parents and kids ramping up adherence to controller medications out of heightened awareness of health risks tied to asthma and COVID-19. It's a classic case of unintended benefits from a global crisis—but does that mean we should discount the therapy's value?
Despite the primary endpoint miss, the good news is that the SQ house dust mite SLIT tablet proved exceptionally well-tolerated over the two-year period. Most side effects were mild or moderate, and fewer than 2% of participants dropped out due to treatment-related issues. Common complaints included local reactions at the application site, such as itching in the mouth or throat, ear itching, or mild upper abdominal discomfort. Crucially, there were no upticks in asthma-related events, no cases of anaphylaxis (a severe allergic reaction), and no need for adrenaline injections in the SLIT group.
As the investigators wrote, the findings from MT-11 and a related MT-12 trial offer crucial safety data to guide decisions on using house dust mite allergen immunotherapy in kids with related respiratory allergies. This could be a game-changer, especially since it's a convenient, at-home treatment that doesn't involve injections.
Yet, this raises some controversial questions: If the pandemic skewed the results, should we still consider SLIT effective for preventing exacerbations? Is the immune system changes enough evidence, or do we need more trials free from external disruptions? Some might argue that the low exacerbation rates during COVID-19 show we've already made huge strides in asthma control through better hygiene and awareness, potentially making immunotherapy less necessary. Others could counter that SLIT's safety profile makes it worth exploring further, especially for families dealing with chronic triggers like dust mites.
What do you think? Should we push forward with immunotherapy for children despite the endpoint not being met, or does this highlight the need for more robust, pandemic-proof studies? Share your thoughts in the comments—do you agree, disagree, or have a personal story to add? And while we're at it, join thousands of clinicians keeping up with the latest in therapies and trial insights by subscribing to HCPLive today.
References
Roberts G, Just J, Nolte H, Hels OH, Emeryk A, Vidal C. SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial. Allergy. 2025;80(12):3401-3411. doi:10.1111/all.70073
Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-1216. doi:10.1016/j.jaci.2009.09.021
